Form 4: Context Therapeutics Director, Karen L. Smith, Acquires Stock Options
SEC Form 4 Filing
Karen L. Smith, a director of Context Therapeutics Inc., acquired stock options on September 4, 2024.
Summary
- On September 4, 2024, Karen L. Smith, a director of Context Therapeutics Inc. [CNTX], acquired 19,315 stock options with an exercise price of $2.43.
- These options vest on the earlier of June 13, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service with the Issuer.
- Following this transaction, Ms. Smith directly owns 19,315 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reporting a transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of transaction: Karen L. Smith acquired stock options. |
| 09/05/2024 | Date of signature of the Form 4 filing. |
| 06/13/2025 | Earliest possible vesting date for the stock options. |
| 09/03/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.